Literature DB >> 16511933

Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.

Andrew J K Ostör1, Edwin R Chilvers, Margaret F Somerville, Anita Y N Lim, Suzanne E Lane, Adrian J Crisp, David G I Scott.   

Abstract

We describe 5 patients with rheumatoid arthritis (RA) who developed pulmonary complications following infliximab therapy; 4 patients had preexisting usual interstitial pneumonia. As the pathophysiology of the pulmonary insult is unknown, we advise caution in the use of anti-tumor necrosis factor-alpha therapy in patients with RA with underlying lung disease of sufficient severity to withhold methotrexate treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16511933

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  27 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 2.  Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Authors:  Carmen Maria Lara Rojas; Elisabetta Borella; Lavinia Palma; Silvio Ragozzino; Enrique De Ramón; Ricardo Gomez-Huelgas; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

3.  Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.

Authors:  Md Yuzaiful Md Yusof; Angela Kabia; Michael Darby; Giovanni Lettieri; Paul Beirne; Edward M Vital; Shouvik Dass; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

Review 4.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 5.  Pulmonary manifestations of Crohn's disease.

Authors:  De-Gan Lu; Xiao-Qing Ji; Xun Liu; Hong-Jia Li; Cai-Qing Zhang
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

6.  Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Elizabeth F Redente; Martin A Aguilar; Bart P Black; Benjamin L Edelman; Ali N Bahadur; Stephen M Humphries; David A Lynch; Lutz Wollin; David W H Riches
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

7.  Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3.

Authors:  L Armstrong; S I H Godinho; K M Uppington; H A Whittington; A B Millar
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

Review 8.  Pulmonary complications of tumor necrosis factor-targeted therapy.

Authors:  Krishna Thavarajah; Peggy Wu; Elisa J Rhew; Anjana K Yeldandi; David W Kamp
Journal:  Respir Med       Date:  2009-02-07       Impact factor: 3.415

9.  Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

Review 10.  Rationale of using different biological therapies in rheumatoid arthritis.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Arthritis Res Ther       Date:  2010-08-24       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.